Pulmonology Department, Hospital General de Granollers.
WASOG Centre of Excellence, Respiratory Institute, Pulmonology Department, Hospital Clínic, Barcelona, Spain.
Curr Opin Pulm Med. 2023 Sep 1;29(5):478-484. doi: 10.1097/MCP.0000000000000985. Epub 2023 Jul 6.
This review provides an assessment of biomarkers in sarcoidosis, aiming to address the need for improved diagnostic, prognostic and management tools. Sarcoidosis presents diagnostic challenges, necessitating the search for reliable biomarkers to guide clinical decisions.
Established biomarkers such as serum angiotensin-converting enzyme (ACE) and serum interleukin-2 receptor (sIL-2R) have limitations in sensitivity and specificity. FDG-PET/CT imaging shows promising results in assessing disease activity and guiding immunosuppression. Gene expression profiling studies reveal potential biomarkers, particularly involving TH1 immune response and IFN-γ-driven signalling pathways. The field of omics sciences offers opportunities for novel biomarker discovery.
These findings have implications for clinical practice and research. The limitations of established biomarkers underscore the need for improved diagnostic tools in sarcoidosis. The potential of FDG-PET/CT imaging requires further exploration. Gene expression profiling and omics sciences offer avenues for discovering novel biomarkers to enhance diagnosis and predict disease progression. Such advancements can facilitate personalized treatment strategies and improve patient outcomes. Continued research is vital to validate the efficacy and clinical applicability of these biomarkers. Overall, this review emphasizes ongoing efforts to advance sarcoidosis biomarkers research and improve disease management.
本综述评估了结节病中的生物标志物，旨在满足对改进诊断、预后和管理工具的需求。结节病的诊断具有挑战性，需要寻找可靠的生物标志物来指导临床决策。
血清血管紧张素转换酶（ACE）和血清白细胞介素-2 受体（sIL-2R）等已确立的生物标志物在灵敏度和特异性方面存在局限性。FDG-PET/CT 成像在评估疾病活动度和指导免疫抑制方面显示出有希望的结果。基因表达谱研究揭示了潜在的生物标志物，特别是涉及 TH1 免疫反应和 IFN-γ 驱动的信号通路。组学科学领域为发现新的生物标志物提供了机会。
这些发现对临床实践和研究具有重要意义。已确立的生物标志物的局限性突出表明需要改进结节病的诊断工具。FDG-PET/CT 成像的潜力需要进一步探索。基因表达谱和组学科学为发现新的生物标志物以增强诊断和预测疾病进展提供了途径。这些进展可以促进个体化治疗策略并改善患者的结局。验证这些生物标志物的疗效和临床适用性的持续研究至关重要。总体而言，本综述强调了推进结节病生物标志物研究和改善疾病管理的持续努力。
